Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
October 05, 2023 16:01 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP
September 26, 2023 07:05 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting
September 11, 2023 12:00 ET
|
Vigil Neuroscience, Inc.
- Complete Phase 1 data analysis demonstrated that VGL101 continued to have a favorable safety and tolerability profile and proof-of-target engagement in SAD/MAD cohorts up to 60 mg/kg - - On track...
Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program
September 08, 2023 16:05 ET
|
Vigil Neuroscience, Inc.
- Announced VG-3927 as lead candidate to enter clinical development for potential treatment of Alzheimer’s Disease - - IND for VG-3927 now open; Phase 1 clinical trial in healthy volunteers allowed...
Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference
September 08, 2023 07:05 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023 07:05 ET
|
Vigil Neuroscience, Inc.
- Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in people living with ALSP expected in fourth quarter of 2023 - - Small molecule TREM2 agonist IND submission and...
Vigil Neuroscience Appoints Christopher J. Silber, M.D. as Chief Medical Officer
August 07, 2023 16:05 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience to Present at 2023 Jefferies Global Healthcare Conference
June 01, 2023 07:00 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update
May 10, 2023 07:00 ET
|
Vigil Neuroscience, Inc.
- Partial clinical hold lifted by FDA on VGL101 - - Launched ALSPAware to provide access to no-cost genetic testing and counseling for ALSP - - Appointed distinguished biopharmaceutical industry...
Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors
May 09, 2023 07:00 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...